This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

57/100

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Risk factors

Topic: Amyloid, tau and blood-test diagnosis

The blood-brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer's disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017). Alzheimer's disease: A matter of blood-brain barrier dysfunction? The Journal of experimental medicine. https://doi.org/10.1084/jem.20171406

Vancouver

Montagne A, Zhao Z, Zlokovic BV. Alzheimer's disease: A matter of blood-brain barrier dysfunction? The Journal of experimental medicine. 2017. doi:10.1084/jem.20171406. PMID: 29061693.

BibTeX

@article{montagne2017-29061693,
  author  = {Montagne, A. and Zhao, Z. and Zlokovic, B. V.},
  title   = {{Alzheimer's disease: A matter of blood-brain barrier dysfunction?}},
  journal = {The Journal of experimental medicine},
  year    = {2017},
  doi     = {10.1084/jem.20171406},
  pmid    = {29061693},
  url     = {https://doi.org/10.1084/jem.20171406}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

An early BBB breakdown and/or dysfunction have been shown in Alzheimer's disease (AD) before dementia, neurodegeneration and/or brain atrophy occur.
However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood.
Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD.
We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder.
Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.

Why it matters

This review discusses evidence that blood-brain barrier breakdown and dysfunction occur early in Alzheimer's disease, before dementia and neurodegeneration, and examines this in animal models. It states the role of blood-brain barrier breakdown is still not fully understood and comments on future approaches as a basis for developing new therapies.

New to this subject? Start with our plain-English guide: Risk factors, ranked →

Study details

Evidence strengthLow

How this study scored 57/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (The Journal of experimental medicine)
Journal's citation record	4 / 4	The Journal of Experimental Medicine: journal h-index 652 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2017 — within 10 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	6 / 7	Cited 671 times (OpenAlex, 2026-10-10)
Citations per year	5 / 5	61.0 citations a year over 11 year(s) since 2017
Impact for its field and year	5 / 6	Cited 24.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 15 other studies in this library
Still being cited	4 / 4	Cited 200 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Berislav V. Zloković: h-index 118 (OpenAlex, whole career)
Institution's track record	2 / 3	University of Southern California: institution h-index 1,521 (OpenAlex)
Multicenter collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 29061693)
Free to read	2 / 2	Free to read
Total	57 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.

Later studies that cite this one

15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Risk factors

Also in Risk factors

356 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.

Similar studies

More on Risk factors

See all studies in Risk factors →